2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Kidney transplantation in m.3243A>G carriers has outcome implications

      letter
      Clinical Kidney Journal
      Oxford University Press

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          With interest we read the article by de Laat et al. about five patients with a mitochondrial disorder (MID) due to the variant m.3243A>G in MT-TL1 clinically manifesting as multisystem disease, with kidney failure as the most prominent feature leading to end-stage renal disease (ESRD) and requiring kidney transplantation [1]. The study has a number of shortcomings. We do not agree that renal involvement in MIDs may only manifest as renal insufficiency with proteinuria, focal segmental glomerulosclerosis (FSGS) or potentially ESRD. In addition to renal insufficiency, FSGS or ESRD kidney involvement in MIDs may also manifest as renal cysts, nephrolithiasis, Fanconi syndrome, renal malignancy or renal infarction secondary to primary mitochondrial cardiomyopathy with atrial fibrillation [2]. Patients receiving a kidney transplant usually require long-term steroids or immunosuppressants. Long-term immunosuppression may be complicated by focal or systemic side effects. One of these possible side effects is muscular compromise (e.g. steroid myopathy, myopathy due to sirolimus) [3]. Since patients carrying the m.3243A>G variant frequently manifest in the skeletal muscle, it is crucial to assess the muscle status prior to transplantation and to monitor muscle function after starting the immunosuppression during follow-up. Thus, we should know how many of the five included patients had clinical or subclinical muscle manifestations prior to transplantation, and in how many immunosuppression either triggered muscle involvement or worsened pre-existing muscle disease. In all five included patients, blood and urine heteroplasmy rates were low. We should know how the authors explain that the m.3243A>G variant was pathogenic and if heteroplasmy rates were also determined in the explanted kidneys. Determining heteroplasmy rates in clinically affected organs or tissues is crucial, as heteroplasmy rates are usually higher in affected than unaffected tissues. Patient 3 had undergone muscle biopsy, thus, it is conceivable that she had undergone determination of heteroplasmy rates in the muscle. Missing is an extensive family history in all five cases. We should know in how many of the patients the MID was inherited and in how many it occurred spontaneously. According to previous data, mitochondrial DNA-related mutations are transmitted via the maternal line in 75% of cases [4], therefore it is conceivable that the variant was inherited from the mother in most or all five patients. Knowing the family history is crucial for determination of the outcome and for genetic counselling of the index patients and their first-degree relatives. Patient 4 presented with epilepsy. Since some of the antiepileptic drugs (AEDs) are not only mitochondrion-toxic but may also cause renal insufficiency (e.g. topiramate, clobazam and perampanel [5]), we should know which AEDs this patient received and if they potentially contributed to kidney dysfunction. Patients carrying the m.3243A>G variant frequently present with stroke-like episodes (SLEs) [6]. Interestingly, none of the five patients was described as having SLEs [1]. Thus, we should know if cerebral imaging was carried out to see if there were remnants of previous SLEs or if there were other manifestations of central nervous system involvement in a MID. In conclusion, the report by de Laat et al. has a number of shortcomings that need to be addressed before drawing final conclusions. Heteroplasmy rates should have been determined in the explanted kidneys to confirm the pathogenicity of the culprit variant. NOTE FROM THE EDITORIAL OFFICE Dr de Laat et al. had no further comments on this letter. AUTHORS’ CONTRIBUTIONS J.F. contributed to design, literature search, discussion, first draft and critical comments. The author read the journal’s position on issues involved in ethical publication. CONFLICT OF INTEREST STATEMENT The results presented in this article have not been published previously in whole or part, except in abstract format.

          Related collections

          Most cited references6

          • Record: found
          • Abstract: found
          • Article: not found

          Genetic Counselling for Maternally Inherited Mitochondrial Disorders.

          The aim of this review was to provide an evidence-based approach to frequently asked questions relating to the risk of transmitting a maternally inherited mitochondrial disorder (MID). We do not address disorders linked with disturbed mitochondrial DNA (mtDNA) maintenance, causing mtDNA depletion or multiple mtDNA deletions, as these are autosomally inherited. The review addresses questions regarding prognosis, recurrence risks and the strategies available to prevent disease transmission. The clinical and genetic complexity of maternally inherited MIDs represent a major challenge for patients, their relatives and health professionals. Since many of the genetic and pathophysiological aspects of MIDs remain unknown, counselling of affected patients and at-risk family members remains difficult. MtDNA mutations are maternally transmitted or, more rarely, they are sporadic, occurring de novo (~25%). Females carrying homoplasmic mtDNA mutations will transmit the mutant species to all of their offspring, who may or may not exhibit a similar phenotype depending on modifying, secondary factors. Females carrying heteroplasmic mtDNA mutations will transmit a variable amount of mutant mtDNA to their offspring, which can result in considerable phenotypic heterogeneity among siblings. The majority of mtDNA rearrangements, such as single large-scale deletions, are sporadic, but there is a small risk of recurrence (~4%) among the offspring of affected women. The range and suitability of reproductive choices for prospective mothers is a complex area of mitochondrial medicine that needs to be managed by experienced healthcare professionals as part of a multidisciplinary team. Genetic counselling is facilitated by the identification of the underlying causative genetic defect. To provide more precise genetic counselling, further research is needed to clarify the secondary factors that account for the variable penetrance and the often marked differential expressivity of pathogenic mtDNA mutations both within and between families.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Mitochondrial metabolic stroke: Phenotype and genetics of stroke-like episodes

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Five non-mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes phenotype adult patients with m.3243A>G mutation after kidney transplantation: follow-up and review of the literature

              Abstract Background Renal involvement in patients with the m.3243A>G mutation may result in end-stage renal disease (ESRD) requiring renal replacement therapy. Although kidney transplantations have been performed in a small number of patients, short- and long-term follow-up data are lacking. Methods We describe five patients with the m.3243A G carriers described in the literature. Results Proteinuria with or without renal failure was the first clinical presentation of renal involvement in 13 of 18 (72%) patients. Focal segmental glomerulosclerosis (FSGS) was found in 9 of 13 (69%) biopsies. Sixteen of 18 (84%) patients developed hearing loss. All patients were diagnosed with diabetes mellitus, of whom eight (44%) developed the disease after transplantation. All patients with reported follow-up data (13/18) had stable kidney function from 6 months to 13 years of follow-up after transplantation. Conclusions Renal involvement in carriers of the m.3243A>G mutation most commonly leads to proteinuria and FSGS and may lead to ESRD. Proper recognition of the mitochondrial origin of the renal disease in these patients is important for adequate treatment selection and suitable supportive care. This case series and review of the available literature on long-term follow-up after kidney transplantation shows it is feasible for non-mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes phenotype carriers of the m.3243A>G mutation to be considered for kidney transplantation in case of ESRD. These patients should not be excluded from transplant solely for their mitochondrial diagnosis.
                Bookmark

                Author and article information

                Journal
                Clin Kidney J
                Clin Kidney J
                ckj
                Clinical Kidney Journal
                Oxford University Press
                2048-8505
                2048-8513
                February 2021
                21 February 2020
                21 February 2020
                : 14
                : 2
                : 723-724
                Affiliations
                Krankenanstalt Rudolfstiftung, Messerli Institute , Vienna, Austria
                Author notes
                Correspondence to: Josef Finsterer; E-mail: fifigs1@ 123456yahoo.de
                Article
                sfaa025
                10.1093/ckj/sfaa025
                7886533
                eeca096a-d370-4ca7-be37-5e26162a0e7b
                © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                : 20 December 2019
                : 29 January 2020
                Page count
                Pages: 2
                Categories
                Letters to the Editor
                AcademicSubjects/MED00340

                Nephrology
                Nephrology

                Comments

                Comment on this article